SCHEMBL6444979

SCHEMBL6444979

C=C(OCC)c1nc(N)nc(SC)c1C#N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.45
MAPT P10636 7/20 0.45
LMNA P02545 4/20 0.45
KDM4E B2RXH2 2/20 0.45
HPGD P15428 2/20 0.45
MEN1 O00255 9/20 0.44
KMT2A Q03164 9/20 0.44
HSD17B10 Q99714 3/20 0.44
CASP1 P29466 2/20 0.44
CASP7 P55210 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 4/20 0.42
HTT P42858 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
STAT6 P42226 1/20 0.42
HIF1A Q16665 1/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6442586 0.76 MAPT (0.48) ALDH1A1MAPTLMNAKDM4EHPGD
SCHEMBL6441876 0.75 ALDH1A1 (0.38) ALDH1A1MAPTLMNAKDM4EHPGD
SCHEMBL967156 0.74 ALDH1A1 (0.59) ALDH1A1MAPTLMNAKDM4EHPGD
SCHEMBL6250094 0.70 ALDH1A1 (0.52) ALDH1A1MAPTLMNAKDM4EHPGD
SCHEMBL7400049 0.69 ALDH1A1 (0.43) ALDH1A1MAPTLMNAKDM4EHPGD
SCHEMBL967753 0.68 ALDH1A1 (0.48) ALDH1A1MAPTLMNAKDM4EHPGD
SCHEMBL4417421 0.66 ALDH1A1 (0.49) ALDH1A1MAPTLMNAKDM4EHPGD
SCHEMBL965018 0.66 ALDH1A1 (0.49) ALDH1A1MAPTLMNAKDM4EHPGD
SCHEMBL6441907 0.66 ALDH1A1 (0.52) ALDH1A1MAPTLMNAKDM4EHPGD
SCHEMBL6442661 0.66 ALDH1A1 (0.49) ALDH1A1MAPTLMNAKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ALDH1A1 534/4885MAPT 1878/4885LMNA 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.